As oncology drug-development costs continue to rise and regulatory pathways become more complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs, according to a recent report by BioMedWire.
Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies, the report states.
Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company's strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate.
Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than focusing on a single product, the report notes.
The shift toward advanced drug delivery comes as the pharmaceutical industry faces escalating R&D costs and regulatory hurdles. By improving the delivery of existing drugs, companies aim to extend product life cycles, reduce development risks and potentially offer better treatment outcomes for patients. Nanotechnology-based delivery systems, for instance, can enhance the solubility and stability of drugs, target tumors more precisely and reduce side effects.
Oncotelic's Deciparticle platform is designed to enable the delivery of small molecules and biologics, potentially improving their therapeutic index. The company's Sapu003 program targets specific cancer pathways using this technology. While still in development, such platforms could address unmet medical needs in oncology and rare diseases.
The industry trend also reflects a broader strategic shift toward platform-based business models, which allow companies to leverage core technologies across multiple product candidates. This approach can reduce per-product development costs and create more value for investors. However, the success of these platforms depends on clinical validation and regulatory approval.
BioMedWire, a specialized communications platform covering biotechnology and life sciences, highlighted that the convergence of nanotechnology, AI and drug delivery could redefine how cancer treatments are developed and administered. The report emphasizes that companies investing in these technologies may be better positioned to compete in an increasingly challenging market.
For more information, visit BioMedWire.
